Articles tagged with: Lenalidomide
Opinion»

From the minute a person is diagnosed with multiple myeloma, he or she is faced with a never-ending series of decisions. Because there are so many ways to approach treatment of the disease, and no consensus among experts on what approach to use, at the end of the day we must make these decisions for ourselves.
As myeloma research advances with the development of new drugs, new treatment combinations, and new studies on the efficacy of transplantation, these decisions become even more difficult. After all, when the choices are limited, it’s easier …
News, Opinion»

What a year 2015 was for the myelomatologist!
The U.S. Food and Drug Administration (FDA) approval of three new myeloma drugs, all within the span of a few weeks towards the end of the year, had already generated great excitement in the community.
Then, several potential practice-changing presentations at the 2015 American Society of Hematology (ASH) annual meeting put the proverbial icing on the cake to round out a landmark year for myeloma therapeutics.
This edition of the myeloma quiz highlights some of the key takeaways from the ASH 2015 meeting.
- …
Press Releases»
- Natco to Acquire License to Sell Generic Lenalidomide in the U.S. Without Volume Limitation commencing in late January, 2026
- License Will Also Provide Natco With a Volume-Limited Entry Beginning in March, 2022 with Anticipated Mid-Single-Digit Percentage Of Capsules Sold In the First 12 Months, Anticipated to Increase Gradually Each Year
Summit, NJ (Press Release) – Celgene Corporation (NASDAQ: CELG) today announced the settlement of litigation with Natco Pharma Ltd. of India, Natco’s U.S. partner, Arrow International Limited, and Arrow’s parent company, Watson Laboratories, Inc. (a wholly-owned subsidiary of Allergan plc) relating to patents for REVLIMID® (lenalidomide).
As part of the settlement, the parties will file Consent Judgments with the United States District Court for the District of New Jersey that enjoin Natco from marketing generic lenalidomide before the expiration of the patents-in-suit, …
Press Releases»

Boudry, Switzerland, and Tokyo (Press Release) – Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that REVLIMID® (lenalidomide), a cancer medicine that is administered orally, has been granted full marketing authorization by Japan’s Ministry of Health, Labour and Welfare (MHLW) for use in combination with dexamethasone as a treatment for patients newly diagnosed with multiple myeloma. This marketing authorization expands upon the approval of REVLIMID in 2010 for the treatment of patients with relapsed or refractory multiple myeloma.
“The approval of REVLIMID as an option for use in …
Press Releases»
Findings Presented at the 57th American Society of Hematology Annual Meeting Demonstrate Activity of KEYTRUDA Therapy in Previously-Treated Multiple Myeloma Patients When Combined with Lenalidomide and Dexamethasone
Kenilworth, NJ (Press Release) – Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today new study findings investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in combination with lenalidomide and low-dose dexamethasone (two commonly used treatments for multiple myeloma) in patients whose disease has progressed after at least two lines of prior therapy, including a proteasome inhibitor and an IMiD (immune modulatory drug). The initial findings from the ongoing Phase 1 KEYNOTE-023 study showed an overall response rate (ORR) of 76 percent (n=13/17), as assessed by …
Press Releases»
Results featured at the 57th Annual American Society of Hematology Meeting and Exposition:
- 72 percent of relapsed or refractory multiple myeloma patients treated with daratumumab combination therapy did not progress or relapse after 18 months of treatment (GEN 503)
- Daratumumab in combination with pomalidomide and dexamethasone produced rapid, deep and durable responses in relapsed and refractory multiple myeloma patients who had received at least two (median of 3.5) prior lines of therapy, including two or more consecutive cycles of lenalidomide and bortezomib, and were refractory to their last line of treatment (MMY1001 Phase1b)
- Single-agent daratumumab demonstrated a median overall survival of 20 months in heavily pre-treated relapsed and refractory multiple myeloma patients who have exhausted other approved treatment options. A partial response or better was achieved by 31 percent of patients, and 83 percent achieved stable disease or better (GEN 501 & MMY2002)
Beerse, Belgium (Press Release) – Janssen-Cilag International NV announced new data from the ongoing Phase 1/2 GEN503 investigational study showing the human CD38-directed monoclonal antibody daratumumab, in combination with lenalidomide and dexamethasone, yielded an overall response rate (ORR) of 81 percent in relapsed or refractory multiple myeloma patients who had received a median of two prior therapies. After 18 months of treatment, investigators observed an overall survival (OS) rate of 90 percent, with 72 percent …
News»

A poster session yesterday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting was the venue for the first substantial dose of multiple myeloma-related presentations at the conference.
During the session, research results were made available for review by meeting attendees in the form of posters, each of which summarized the results of a single study. As is typically the case during such sessions, each poster was about two feet high by three or four feet in length. All posters were displayed throughout a large conference hall.
Most of the …